HMG-CoA reductase inhibitors and the risk of fractures

JAMA

Volumn 283, Issue 24, 2000, Pages 3205-3210

  Meier, Christoph R ^a,c,d   Schlienger, Raymond G ^a,c   Kraenzlin, Marius E ^b   Schlegel, Brigitta ^a   Jick, Hershel ^d  

^a Hoffmann La Roche   (Switzerland)

^b Div Endocrinol Diabet Clin N   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BODY MASS; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0034725352     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.24.3205     Document Type: Article

References (21)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet. 1994;344: 1383-1389.
2. Byington RP, Jukema W, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation. 1995; 92:2419-2425.
3. West of Scotland Coronary Prevention Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS), Circulation. 1998;97:1440-1445.
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med. 1995;333:1301-1307.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
6. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
7. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-1949.
8. Wang GJ, Chung KC, Shen WJ. Lipid clearing agents in steroid-induced osteoporosis. J Formos Med Assoc. 1995;94:589-592.
9. Cui Q, Wang GJ, Su CC, Balaian G. The Otto Aufranc award: lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop. 1997;344: 8-19.
10. Bauer DC, Mundy GR, Jamal SA, et al. Statin use, bone mass and fracture: an analysis of two prospective studies [abstract]. J Bone Miner Res. 1999;14 (suppl 1):S179.
11. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab. 2000;85:1137-1142.
12. Jick H. A database worth saving. Lancet. 1997; 350:1045-1046.
13. Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997;350:1097-1099.
14. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45: 419-425.
15. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ. 1991;302:766-768.
16. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf. 1992;1:347-349.
17. Pedrazzoni M, Alfano FS, Gatti C, et al. Acute effects of biphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int. 1995;57:25-29.
18. Gamero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinel Metab. 1994;79:1693-1700.
19. Wolff I, van Croonenborg JJ, Kemper HC, Kostense PJ, Twisk JW. The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int. 1999;9:1-12.
20. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med. 1991;325:1189-1195.
21. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ. Incidence of clinically diagnosed vertebral fractures: a population based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992;7:221-227.